Japan’s M3 acquires majority share in Bengaluru-based DailyRounds

Neuroglia Health owns and operates “DailyRounds" mobile app, which enables case-based problem-solving for doctors. Neuroglia Health also runs “Marrow" which is a test-preparation platform aimed at post-graduate specialty courses in medical schools in India.

This move marks M3’s foray into case-based problem-solving community platform and medical test preparation business in India, in addition to its existing business Health Impetus Private Ltd. (HIPL).

HIPL, owned by M3 India, currently runs an online portal that help doctors stay up-to-date with the latest research material, medical news, evidence-based medicine, practice guidelines, and expert articles.

“With this majority acquisition, M3 India will now be able to reach out to 450,000 doctors in India on a consolidated basis, while enhancing the utility and satisfaction levels among Doctors by leveraging the strengths of both platforms. It will also enable M3 India to escalate its marketing support and market research businesses to pharmaceutical and medical devices," said Amit Singh, chief executive of HIPL in a statement.

“We are very excited with this development. With the support of M3 we will be offer better services to the existing doctors. Further, we hope to bring in new doctors as well. The goal is to be largest doctor network in India, not just by registered numbers, but in terms of active users as well," added Dr. Deepu Sebin, chief executive of Neuroglia Health.

M3 also intends to import services and technologies developed in Japan and internationally into India, such as job placement support services and AI applications, with an aim to build next-generation healthcare technologies in India.

M3 also operates m3.com, an online portal for medical professionals that delivers healthcare-related information to its over 270,000 physician members in Japan and over 4.5 million physician members globally. M3.com offers marketing, clinical trial, and various other services to healthcare and pharmaceutical industries.